Liver and Bone Metastases From Small Bowel Neuroendocrine Tumor Respond to 177Lu-DOTATATE Induction and Maintenance Therapies

被引：3

作者：

Makis, William ^{[1
]}

McCann, Karey ^{[1
]}

Buteau, Francois A. ^{[1
]}

McEwan, Alexander J. B. ^{[1
]}

机构：

[1] Cross Canc Inst, Dept Diagnost Imaging, Edmonton, AB T6G 1Z2, Canada

来源：

CLINICAL NUCLEAR MEDICINE | 2015年 / 40卷 / 02期

关键词：

lutetium; Lu-177-DOTATATE; PRRT; bone metastases; carcinoid; neuroendocrine tumor; RECEPTOR RADIONUCLIDE THERAPY;

D O I：

10.1097/RLU.0000000000000569

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

A 73-year-old man diagnosed with small bowel neuroendocrine tumor (NET) with liver and bone metastases was treated with 4 induction cycles and 2 maintenance cycles of Lu-177-DOTATATE peptide receptor radionuclide therapy (PRRT). His symptoms and mobility improved significantly following induction as well as maintenance treatments, and posttherapy imaging studies showed significant improvement in metastatic liver and bone disease. Current protocols consisting of 4 induction cycles of Lu-177-DOTATATE only may not be sufficient to optimally treat neuroendocrine liver and bone metastases, and further research into maintenance Lu-177-DOTATATE therapy is warranted.

引用

页码：162 / 165

页数：4

共 14 条

[1] Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence
Campana, Davide
Capurso, Gabriele
Partelli, Stefano
Nori, Francesca
Panzuto, Francesco
Tamburrino, Domenico
Cacciari, Giulia
Delle Fave, Gianfranco
Falconi, Massimo
Tomassetti, Paola
[J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 (08) : 1197 - 1205
[2] Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours
Claringbold, Phillip G.
Brayshaw, Paul A.
Price, Richard A.
Turner, J. Harvey
[J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (02) : 302 - 311
[3] Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy
Ezziddin, Samer
Opitz, Martin
Attassi, Mared
Biermann, Kim
Sabet, Amir
Guhlke, Stefan
Brockmann, Holger
Willinek, Winfried
Wardelmann, Eva
Biersack, Hans-Juergen
Ahmadzadehfar, Hojjat
[J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (03) : 459 - 466
[4] Carcinoid metastasis to the brain
Hlatky, R
Suki, D
Sawaya, R
[J]. CANCER, 2004, 101 (11) : 2605 - 2613
[5] Lutetium-labelled peptides for therapy of neuroendocrine tumours
Kam, B. L. R.
Teunissen, J. J. M.
Krenning, E. P.
de Herder, W. W.
Khan, S.
van Vliet, E. I.
Kwekkeboom, D. J.
[J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : 103 - 112
[6] Kos-Kudla Beata, 2008, Endokrynol Pol, V59, P41
[7] Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors
Kwekkeboom, Dik J.
de Herder, Wouter W.
van Eijck, Casper H. J.
Kam, Boen L.
van Essen, Martijn
Teunissen, Jaap J. M.
Krenning, Eric P.
[J]. SEMINARS IN NUCLEAR MEDICINE, 2010, 40 (02) : 78 - 88
[8] Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3] octreotate in patients with endocrine gastroenteropancreatic tumors
Kwekkeboom, DJ
Teunissen, JJ
Bakker, WH
Kooij, PP
de Herder, WW
Feelders, RA
van Eijck, CH
Esser, JP
Kam, BL
Krenning, EP
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (12) : 2754 - 2762
[9] Thirteen-Month Registration of Patients with Gastroenteropancreatic Endocrine Tumours in France
Lombard-Bohas, C.
Mitry, E.
O'Toole, D.
Louvet, C.
Pillon, D.
Cadiot, G.
Borson-Chazot, F.
Aparicio, T.
Ducreux, M.
Lecomte, T.
Etienne, P. L.
Cacheux, W.
Legoux, J. L.
Seitz, J. F.
Ruszniewski, P.
Chayvialle, J. A.
Rougier, P.
[J]. NEUROENDOCRINOLOGY, 2009, 89 (02) : 217 - 222
[10] Meijer WG, 2003, J NUCL MED, V44, P184

← 1 2 →